APIC-CF Therapy for Mild to Moderate Osteoarthritis of the Knee
A Phase I/II, Multicenter, Double-Blind, Placebo-controlled Safety and Efficacy Study to Evaluate APIC-CF Therapy for Mild to Moderate Primary Osteoarthritis of the Knee
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Gaetano Scuderi, MD
- Phone Number: 1 561-575-4451
- Email: scuderimd@aol.com
Study Locations
-
-
Maryland
-
Townsend, Maryland, United States, 21204
- Recruiting
- IRC Clinical
-
Contact:
- Kendra Barton, RN, BSN
- Phone Number: 443-275-1599
- Email: kendra.barton@ircclinical.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient provides signed written informed consent
- The patient is willing and able to complete effectiveness and safety questionnaires and is able to read and understand study instructions in English.
- Patient is a male or female aged between 21 - 70 years of age at the time of informed consent.
- Patient is ambulatory (assistive devices allowed if used 4 weeks or more prior to Screening).
- Patient has symptomatic OA in the target knee
- Patient has a radiographic confirmation of OA at the target knee prior to screening with a grade II or III score on the K-L grading scale (Kellgren, 1957)using radiographs performed within 24 weeks of Screening
- The patient has knee pain as demonstrated by a score of ≤3 on the KOOS pain subscale
- The patient has venous access sufficient for APIC-CF production
Exclusion Criteria:
The patient has any of the following:
- Grade 4 score on the K-L grading scale for the target knee
- Grade 3 score on the K-L grading scale and exhibits at least one Grade 4 characteristic (large osteophytes, marked narrowing of joint space, severe sclerosis, or definite deformity of bone contour).
- Acute fracture of the lower limb.
- Medical history of severe bone disease (e.g., osteoporosis, osteonecrosis, joint deformity, instability, or septic arthritis).
- The patient is categorized as grossly obese, defined as body mass index (BMI) greater than 35 kg/m2
- Hemoglobin values <11 g/dL
- Pregnant or breastfeeding women
- Has clinically apparent tense effusion of the target knee.
- Has had chondrocyte transplantation or reconstruction of ligaments in the target knee.
- Has received an intra-articular injection(s) into any joint (e.g., corticosteroids or chondroprotective agents) within 60 days prior to Screening. Subjects receiving a corticosteroid injection during the study will be withdrawn from the study.
- Has had surgery to the target knee within 12 months or arthroscopy of the target knee within 90 days prior to Screening.
- Has an inflammatory disease of either knee other than OA (e.g., rheumatoid arthri septic arthritis).
- Has another disease that can affect the health of the knee (e.g., chronic hemochromatosis; sickle cell anemia; arthropathies of systemic diseases such as chondrocalcinosis, gout, pseudogout, psoriasis, hemophilia, and infectious diseases of the joints).
- Has significant joint infection in the target knee or inflammatory or skin disorder in the injection area of the target knee.
- Septic arthritis in any joints within 1 year prior to screening;
- Has fibromyalgia, anserine bursitis, lumbar radiculopathy, neurogenic or vascular claudication, vascular insufficiency of lower limbs, or peripheral neuropathy severe enough to interfere with the study evaluations.
- Patella femoral instability
- Patients with a history of cartilage allograft, autograft or microfracture in the study knee
- Patients with a history of any type of blood coagulation or bleeding disorder, currently taking warfarin or other parental anticoagulant therapy or history of DVT/PE during <1 year of Screening.
- Has a systemic or other disease or significant liver function test result from screening that, in the opinion of the investigator, would interfere with study evaluation or have an impact on the balance of benefits and risks of study treatment.
Diseases that may interfere:
- type 1 diabetes
- immunodeficiency syndrome
- significant cardiovascular, renal, or liver disease
- severe anemia
- severe thrombocytopenia
- severe infectious disease with or without fever.
- any significant chronic skin disorders, active skin or soft tissue infection that could interfere with the evaluation of the injection site.
- mal-alignment/deformity of the leg
- active asthma that may require periodic treatment with steroids during the study period
- active malignancy receiving treatment, or prior history of any malignancy, with the exception of basal cell carcinoma of the skin treated more than 1 year ago
- Patients with psychiatric or neurological disorders including cognitive impairment or inability to provide informed consent
- Incarcerated or confined patients
- Medical-legal, personal injury, ongoing litigation or worker's compensation claim
- History of drug abuse
- Use of investigational drug, device, or biologic within 12 weeks of screening
- Any condition that, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Saline
|
Placebo Comparator: Saline
|
|
Experimental: APIC-CF 4cc,
APIC-CF 4cc, once at first day
|
|
|
Experimental: APIC-CF, 2cc
APIC-CF, 2cc, one at first day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction in pain after 8 weeks
Time Frame: 8 weeks
|
Statistically significant reduction in pain after 8 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score
|
8 weeks
|
|
Reduction in pain while walking at 8 weeks
Time Frame: 8 weeks
|
Statistically significant reduction in pain while walking after 8 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score
|
8 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Reduction in pain after 2 weeks
Time Frame: 2 weeks
|
Statistically significant reduction in pain after 2 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score.
|
2 weeks
|
|
Reduction in pain while walking at 2 weeks
Time Frame: 2 weeks
|
Statistically significant reduction in pain while walking after 2 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score
|
2 weeks
|
|
Reduction in pain at 24 weeks
Time Frame: 24 weeks
|
Statistically significant reduction in pain after 24 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score
|
24 weeks
|
|
Reduction in pain while walking after 24 weeks
Time Frame: 24 week
|
Statistically significant reduction in pain while walking after 24 weeks from initial treatment of APIC-CF compared to control as determined by the Knee injury and Osteoarthritis Outcome Score (KOOS) total score
|
24 week
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- Cyt300-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.